Elucidation of the role of 2 novel cross presentation genes

阐明 2 个新型交叉表达基因的作用

基本信息

  • 批准号:
    9883698
  • 负责人:
  • 金额:
    $ 41.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Dendritic cells (DCs) and macrophages are capable of acquiring and then displaying peptides from external antigens through a process called cross presentation. This process is the key mechanism that allows the immune system to recognize and then mobilize a CD8 T cell response to cancers, many viral infections and intracellular pathogens. Consequently, this pathway is important for immune surveillance and is an attractive target to enable vaccines to elicit CD8 T cell immunity. Given this, it is important to elucidate te mechanisms that allow DCs to carry out this critical function and this is the overall goal of this grant. To this end, we propose to characterize and elucidate the function of two key and previously unsuspected novel cross presentation genes that we discovered in an unbiased, genome-wide forward genetic screen. Our first Aim will elucidate the role of Rab39A in cross presentation. Very interestingly, while Rab39A is required for cross presentation but not conventional MHC I or MHC II presentation. Rab proteins are GTPases that control the formation, content, trafficking and ultimate fusion of vesicles in cells and thereby determine the composition of endocytic compartments. Our favored hypothesis is that Rab39A is functioning to help form a specialized XPT compartment in DCs by trafficking essential components of the XPT pathway. Furthermore, given their role in determining the composition of vesicles, Rabs and their recruited effectors serve as markers to identify and isolate unique endocytic compartments (e.g. early endosomes, late endosomes, lysosomes, melanosomes, etc.). In this context, and very interestingly, Rab39A is only present in a subset of phagosomes in DCs. Given this, we also hypothesize that Rab39A will mark the XPT compartment. The importance of these hypotheses is that Rab39A could solve the mystery as to how MHC I and/or other components from the ER get to phagosomes; clarify where XPT is carried out and its relationship to other pathways such as MHC II; and/or allow the characterization of the Rab39A+ compartment to identify novel components in the pathway. This Aim will test these hypotheses and more generally explore and elucidate the role of Rab39A in XPT. Our second Aim will elucidate the role of Loc547349 (Loc) in cross presentation. Our preliminary data show that this molecule is required for cross presentation but not classical MHC I or MHC II antigen presentation. Very interestingly, Loc is an MHC-encoded MHC I-like molecule of unknown function. This discovery is very intriguing because many of the key genes for MHC I and MHC II antigen presentation are encoded in the MHC locus. Moreover, there is a similar molecule, HLA-DM, that operates as a peptide editor in the MHC II pathway and for which up until now has not had a clear counterpart in the MHC I pathway, yet there is a theoretical need for such an activity for cross presentation. Our favored hypotheses are that Loc functions in cross presentation to help traffic MHC I molecules to endocytic compartments, stabilize them, and/or load them with peptides. The goal of this aim is to test this hypothesis as well as other potential functions and elucidate the role of Loc in cross presentation.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH L ROCK其他文献

KENNETH L ROCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH L ROCK', 18)}}的其他基金

Novel histone-binding C-type lectin receptors and their role in sterile inflammation and tissue injury
新型组蛋白结合 C 型凝集素受体及其在无菌炎症和组织损伤中的作用
  • 批准号:
    10566947
  • 财政年份:
    2022
  • 资助金额:
    $ 41.88万
  • 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
  • 批准号:
    10204986
  • 财政年份:
    2020
  • 资助金额:
    $ 41.88万
  • 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
  • 批准号:
    10414938
  • 财政年份:
    2020
  • 资助金额:
    $ 41.88万
  • 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
  • 批准号:
    10667446
  • 财政年份:
    2020
  • 资助金额:
    $ 41.88万
  • 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
  • 批准号:
    9797712
  • 财政年份:
    2019
  • 资助金额:
    $ 41.88万
  • 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
  • 批准号:
    10392945
  • 财政年份:
    2019
  • 资助金额:
    $ 41.88万
  • 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
  • 批准号:
    10606598
  • 财政年份:
    2019
  • 资助金额:
    $ 41.88万
  • 项目类别:
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis
Clec2d-DAMP 相互作用在组织损伤和脓毒症病理生理学中的作用
  • 批准号:
    10164709
  • 财政年份:
    2017
  • 资助金额:
    $ 41.88万
  • 项目类别:
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
Tspan5 在 MHC I 抗原呈递和癌症免疫逃避中的作用
  • 批准号:
    10210168
  • 财政年份:
    2016
  • 资助金额:
    $ 41.88万
  • 项目类别:
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
Tspan5 在 MHC I 抗原呈递和癌症免疫逃避中的作用
  • 批准号:
    10362713
  • 财政年份:
    2016
  • 资助金额:
    $ 41.88万
  • 项目类别:

相似海外基金

RNA vaccine that exerts antitumor effect via non-canonical antigen presentation pathway
通过非经典抗原呈递途径发挥抗肿瘤作用的RNA疫苗
  • 批准号:
    19K07782
  • 财政年份:
    2019
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Climate change and fish disease: In vivo and in vitro studies of the modulation of the teleost antigen presentation pathway in response to thermal stress and viral infection using two different system
气候变化和鱼类疾病:使用两种不同的系统对硬骨鱼抗原呈递途径的调节响应热应激和病毒感染进行体内和体外研究
  • 批准号:
    469000-2014
  • 财政年份:
    2015
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Banting Postdoctoral Fellowships Tri-council
Climate change and fish disease: In vivo and in vitro studies of the modulation of the teleost antigen presentation pathway in response to thermal stress and viral infection using two different system
气候变化和鱼类疾病:使用两种不同的系统对硬骨鱼抗原呈递途径的调节响应热应激和病毒感染进行体内和体外研究
  • 批准号:
    469000-2014
  • 财政年份:
    2014
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Banting Postdoctoral Fellowships Tri-council
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    8652945
  • 财政年份:
    2012
  • 资助金额:
    $ 41.88万
  • 项目类别:
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    8466919
  • 财政年份:
    2012
  • 资助金额:
    $ 41.88万
  • 项目类别:
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    9054767
  • 财政年份:
    2012
  • 资助金额:
    $ 41.88万
  • 项目类别:
Herpes simplex virus-1 evasion of CD1d antigen presentation pathway
单纯疱疹病毒-1逃避CD1d抗原呈递途径
  • 批准号:
    8373738
  • 财政年份:
    2012
  • 资助金额:
    $ 41.88万
  • 项目类别:
Investigation of the HLA class II Antigen Presentation Pathway in Estrogen Receptor Negative and Estrogen Receptor Positive Breast Carcinoma.
雌激素受体阴性和雌激素受体阳性乳腺癌中 HLA II 类抗原呈递途径的研究。
  • 批准号:
    186899
  • 财政年份:
    2009
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Fellowship Programs
Down regulation of antigen presentation pathway plays an important role in metastasis and progression of advanced stage of epithelial ovarian cancer.
抗原呈递途径的下调在上皮性卵巢癌晚期的转移和进展中发挥重要作用。
  • 批准号:
    21390449
  • 财政年份:
    2009
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
New anti-tuberculosis vaccine strategies by the use of the CD1-lipid antigen presentation pathway
利用 CD1-脂质抗原呈递途径的新抗结核疫苗策略
  • 批准号:
    15390317
  • 财政年份:
    2003
  • 资助金额:
    $ 41.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了